TrialResults - center   -  Clinical trials results database in


Table summary of clinical trials for lixisenatide back     pdf    short list

Clinical trials of lixisenatide (ZP10A peptide, AVE 0010, AVE0010, AVE-0010, Lixisenatide, AQVE-10010, ) are available for the clinical conditions:


Diabetes type 2

These trials are included in meta-analysis concerning: insulin secretagogues peptides (incretins) in all type of patients, antidiabetic drugs in patients inadequately controlled on monotherapy, antidiabetic drugs in patients with insufficient glycaemic control with bitherapy, antidiabetic drugs in patients inadequately controlled with insulin, antidiabetic drugs in patients inadequately controlled on metformin, insulin therapy in all type of patients, glucose lowering for cardiovascular prevention in all type of patients, antidiabetic drugs in Patients inadequately controlled on MET+SU therapy,

RESTORE
NCT00931372

versus
  Follow-up:

 
BDR11578
NCT01146678

versus
  Follow-up:

Germany 
lixisenatide vs control
GETGOAL-MONO Japan LTS (ongoing)
NCT00905255
AVE0010 once daily treatment in monotherapy
versus
usual care
type 2 diabetes patients   Follow-up: 24-76 weeks
open
Japan 
lixisenatide vs glargine once daily
GETGOAL-L (unpublished)
NCT00715624
AVE0010 (10,15 and 20 µg) in association with basal insulin, with or without metformin
versus
placebo on top basal insulin
Type 2 diabetes mellitus insufficiently controlled with basal insulin with or without metformin  Follow-up: 24 weeks
double-blind
USA 
lixisenatide vs placebo
ELIXA (EFC11319) (ongoing)
NCT01147250
Lixisenatide 20 µg one daily
versus
placebo
type 2 diabetic patients who experienced an acute coronary syndrome  Follow-up:
double-blind
USA 
GETGOAL-MONO (ongoing)
NCT00688701
AVE0010 in monotherapy
versus
lixisenatide
Type 2 diabetes mellitus not treated with any antidiabetic agent  Follow-up: 12 weeks
double-blind
USA 
lixisenatide vs placebo (add on basal insulin)
GetGoal Duo1 (ongoing)
NCT00975286
Lixisenatide as an add-on treatment to insulin glargine and metformin
versus
placebo
patients with type 2 diabetes insufficiently controlled with insulin glargine and metformin  Follow-up: 24 weeks
double-blind
USA 
GETGOAL-L (unpublished)
NCT00715624
AVE0010 (10,15 and 20 µg) in association with basal insulin, with or without metformin
versus
placebo on top basal insulin
Type 2 diabetes mellitus insufficiently controlled with basal insulin with or without metformin  Follow-up: 24 weeks
double-blind
USA 
GETGOAL-L-ASIA (ongoing)
NCT00866658
24 weeks of AVE0010
versus
placebo on Top of Basal Insulin +/- Sulfonylurea
Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea  Follow-up: 24 weeks
double-blind
Japan 
lixisenatide vs placebo (add on MET)
Ratner DRI6012 ,2010
NCT00299871
subcutaneous lixisenatide doses of 5, 10, 20 or 30 microg once daily or twice daily
versus
placebo
patients with Type 2 diabetes inadequately controlled with metformin (>= 1000 mg/day)  Follow-up: 13 weeks
double-blind (nature not volume)
multinational 
GETGOAL-F1 (ongoing)
NCT00763451
AVE0010 in association with metformin
versus
placebo
Type 2 diabetes mellitus insufficiently controlled with metformin  Follow-up: 24 weeks
double-blind
USA 
GETGOAL-M (ongoing)
NCT00712673
AVE0010 in association with metformin
versus
Type 2 diabetes mellitus insufficiently controlled with metformin  Follow-up: 24 weeks
double-blind
USA 
lixisenatide vs placebo (add on MET+/-SU)
GetGoal-M-As (ongoing)
NCT01169779
Lixisenatide (Titration phase: 10 µg maintenance phase: 20 µg, add-on treatment to metformin with or without sulfonylurea
versus
add-on treatment to metformin with or without sulfonylurea
  Follow-up: 24 weeks
double-blind
China 
lixisenatide vs placebo (add on SU+/-MET)
GETGOAL-S (ongoing)
NCT00713830
AVE0010 in association with sulfonylurea without or with metformin
versus
placebo
patients with type 2 diabetes not adequately controlled with sulfonylurea  Follow-up: 24 weeks
double-blind
USA 
lixisenatide vs placebo (add on TZD+/-MET)
GETGOAL-P (ongoing)
NCT00763815
AVE0010 in association with pioglitazone with or without metformin
versus
placebo
Type 2 diabetes mellitus insufficiently controlled with pioglitazone with or without metformin  Follow-up: 24 weeks
double-blind
USA 
lixisenatide vs exenatide
GetGoal-X (ongoing)
NCT00707031
AVE0010 in association with metformin
versus
exenatide in association with metformin
type 2 diabetes  Follow-up: 24 weeks
open
USA 
lixisenatide vs liraglutide
PDY10931
NCT01175473
lixisenatide
versus
liraglutide
  Follow-up:

germany 
lixisenatide vs sitagliptin (add on MET)
EFC10780 ,2010 (ongoing)
NCT00976937
Lixisenatide titrated 15-20 µg once daily
versus
Sitagliptin (add-on to Metformin)
Obese Type 2 Diabetic Patients Younger Than 50   Follow-up: 24 weeks
double-blind
WW 



Entry terms: AVE 0010, ZP10A peptide, AVE 0010, AVE0010, AVE-0010, Lyxumia, AQVE-10010, Lixisenatide, Zealand Pharma Brand of Lixisenatide




Search lixisenatide clinical trials in Pubmed

Search lixisenatide clinical trials in ClinicalTrials.gov

Search lixisenatide clinical trials in Wikipedia

Search lixisenatide in drugs.com




tableau_trt

 
(c) 2006-2014TrialResults-center - All rights reserved Sitemap | Feedback | Disclaimer & Privacy Policy | Copyright | Home | Top
Last uptaded on 2014/4
124 user(s) connected

Creative Commons License TrialResults-center database by TrialResults-center is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France License .


OpenSearch feed - Add TrialResults-center.org to your browser's search bar